Compared with conventional IgG molecules, VHH antibodies that derive from camelid heavy chain only antibodies (HCAbs) possess many unique and favorable properties of size, solubility, stability, immunogenicity, recognition of uncommon or hidden epitopes, format engineering and manufacturability, and have manifested medical potential both as diagnosis reagents and in therapeutic drug development.
Phage display is the dominant approach for VHH antibody discovery. Unfortunately, its capability is heavily subject to antibody expression bias, protein folding errors, low screening efficiency, and loss of diversity.
DetaiBio alpaca SingleB® VHH discovery platform is an excellent alternate. Armed with our SmartFlow® FACS mAb Discovery platform and DeepLight® screening technology, DetaiBio R&D team is experienced in providing SingleB® Alpaca VHH antibody fast discovery service: we are able to deliver certain amount of unique, FACS-validated VHH antibody candidates as fast as 90 days after 1st immunization shot. Similar with our cases of other host species, before us losing them, both memory B cells and plasma cells are directly screened to cover most B cell clones, thus guaranteeing maximal CDR diversity of antibody hits.
Camelid heavy-chain antibody
Based on its structural specificity, VHH integrates the advantages of traditional antibodies and small molecule drugs:
90-day High Delivery
Deliver 50 FACs binders
& VHH sequence
double screening, double guarantee
with multiple on-chip assay
Higher antibody affinity
Basically eliminate immunogenicity
|Stage Ⅰ Animal Immunization
|Stage Ⅱ “1+1”Double Screening
|Stage Ⅲ BGE® HTP Expression & Functional Test
|Stage Ⅳ Monoclonal Antibody Gene Sequencing
Expression and Purification of Recombinant Antibody (optional)